Multicenter Clinical Study on Piperacillin/Sulbactam for Treatment of Respiratory and Urinary Tract Infection

Objection: To evaluate the efficacy and safety of piperacillin-sulbactam(2︰1) in treatment of moderate to severe degree respiratory and urinary tract infections comparing with piperacillin-tazobactam(8︰ 1).Methods: A randomized,double-blind,parallel controlled,multicenter trial was conducted,and the doses of piperacillin-sulbactam and piperacillin-tazobactam were 6.0 g and 4.5 g,bid for 7-10 days,respectively.The total number of final evaluated subjects was 203 including 100 subjects in piperacillin-sulbactam group and 103 subjects in piperacillin-tazobactam group.The bacterial evaluated subjects were 93 for piperacillin-sulbactam group and 83 for piperacillin-tazobactam group.Results: Clinical efficacy rate,bacterial eradication rate,and incidence of adverse reaction for piperacillin-sulbactam group was 95.0%,90.0%,and 6.8%,for piperacillin-tazobactam group was 91.3%,95.1%,and 4.8%,respectively.Serious adverse drug reaction did not occur in the two groups.Conclusion: Piperacillin-sulbactam had an excellent clinical efficacy and good safety profile in treating patients with moderate to severe degree respiratory and urinary tract bacterial infections.